ErbB2 pathway activation upon smad4 loss promotes lung tumor growth and metastasis

Cell Reports

Volumn 10, Issue 9, 2015, Pages 1599-1613

  Liu, Jian ^a   Cho, Sung Nam ^a   Akkanti, Bindu ^a   Jin, Nili ^a   Mao, Jianqiang ^a   Long, Weiwen ^b   Chen, Tenghui ^c   Zhang, Yiqun ^a   Tang, Ximing ^c   Wistub, IgnacioI ^c   Creighton, ChadJ ^a,c   Kheradmand, Farrah ^a   DeMayo, FrancescoJ ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB RECEPTOR FEEDBACK INHIBITOR 1; LAPATINIB; MESSENGER RNA; PICTILISIB; PROTEIN KINASE B; SMAD4 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF3; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS MUCOSA; CANCER GROWTH; CANCER INHIBITION; CELL HYPERPLASIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TARGETING; ELF3 GENE; EPITHELIUM CELL; ERBB2 GENE; ERRFI1 GENE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE LOSS; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMAD4 GENE; TRANSCRIPTOMICS; TUMOR INVASION;

MUS;

EID: 84924530354     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.02.014     Document Type: Article

References (56)

1. Ahmad I., Patel R., Singh L.B., Nixon C., Seywright M., Barnetson R.J., Brunton V.G., Muller W.J., Edwards J., Sansom O.J., Leung H.Y. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc. Natl. Acad. Sci. USA 2011, 108:16392-16397.
2. Anastasi S., Sala G., Huiping C., Caprini E., Russo G., Iacovelli S., Lucini F., Ingvarsson S., Segatto O. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 2005, 24:4540-4548.
3. Arcila M.E., Chaft J.E., Nafa K., Roy-Chowdhuri S., Lau C., Zaidinski M., Paik P.K., Zakowski M.F., Kris M.G., Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 2012, 18:4910-4918.
4. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
5. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511:543-550. Cancer Genome Atlas Research Network.
6. Coppe J.-P., Amend C., Semeiks J., Baehner F.L., Bayani N., Campisi J., Benz C.C., Gray J.W., Neve R.M. ERBB receptor regulation of ESX/ELF3 promotes invasion in breast epithelial cells. Open Cancer J. 2010, 3:89-100.
7. Davé V., Wert S.E., Tanner T., Thitoff A.R., Loudy D.E., Whitsett J.A. Conditional deletion of Pten causes bronchiolar hyperplasia. Am. J. Respir. Cell Mol. Biol. 2008, 38:337-345.
8. de Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J.Natl. Cancer Inst. 2000, 92:1388-1402.
9. Dennis J.L., Hvidsten T.R., Wit E.C., Komorowski J., Bell A.K., Downie I., Mooney J., Verbeke C., Bellamy C., Keith W.N., Oien K.A. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res. 2005, 11:3766-3772.
10. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., Perry S.R., Labrot E.S., Wu X., Lis R., et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
11. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J.Med. Chem. 2008, 51:5522-5532.
12. Greulich H., Kaplan B., Mertins P., Chen T.H., Tanaka K.E., Yun C.H., Zhang X., Lee S.H., Cho J., Ambrogio L., et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl. Acad. Sci. USA 2012, 109:14476-14481.
13. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., Liewehr D.J., Steinberg S.M., Merino M.J., Rubin S.D., Steeg P.S. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J.Natl. Cancer Inst. 2008, 100:1092-1103.
14. Hackel P.O., Gishizky M., Ullrich A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 2001, 382:1649-1662.
15. Han X., Li F., Fang Z., Gao Y., Li F., Fang R., Yao S., Sun Y., Li L., Zhang W., et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 2014, 5:3261.
16. SEER Cancer Statistics Review, 1975-2011 2014, National Cancer Institute, Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. http://seer.cancer.gov/csr/1975_2011/, N. Howlader, A. Noone, M. Krapcho, N. Neyman, R. Aminou, S.F. Altekruse, C.L. Kosary, J. Ruhl, Z. Tatalovich, H. Cho (Eds.).
17. Iwanaga K., Yang Y., Raso M.G., Ma L., Hanna A.E., Thilaganathan N., Moghaddam S., Evans C.M., Li H., Cai W.W., et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 2008, 68:1119-1127.
18. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
19. Jeon H.S., Jen J. TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J.Thorac. Oncol. 2010, 5:417-419.
20. Ke Z., Zhang X., Ma L., Wang L. Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis. Neoplasma 2008, 55:323-329.
21. Langer C.J., Stephenson P., Thor A., Vangel M., Johnson D.H. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J.Clin. Oncol. 2004, 22:1180-1187. Eastern Cooperative Oncology Group Study 2598.
22. Lee P.C., Lo C., Lin M.T., Liang J.T., Lin B.R. Role of surgical intervention in managing gastrointestinal metastases from lung cancer. World J. Gastroenterol. 2011, 17:4314-4320.
23. Lesche R., Groszer M., Gao J., Wang Y., Messing A., Sun H., Liu X., Wu H. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002, 32:148-149.
24. Li H., Cho S.N., Evans C.M., Dickey B.F., Jeong J.W., DeMayo F.J. Cre-mediated recombination in mouse Clara cells. Genesis 2008, 46:300-307.
25. Lin C.I., Du J., Shen W.T., Whang E.E., Donner D.B., Griff N., He F., Moore F.D., Clark O.H., Ruan D.T. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J.Clin. Endocrinol. Metab. 2011, 96:E554-E565.
26. Liu F. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar etal., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res., 7: 4115-4121, 2001. Clin. Cancer Res. 2001, 7:3853-3856.
27. Malkoski S.P., Cleaver T.G., Thompson J.J., Sutton W.P., Haeger S.M., Rodriguez K.J., Lu S.L., Merrick D., Wang X.J. Role of PTEN in basal cell derived lung carcinogenesis. Mol. Carcinog. 2014, 53:841-846.
28. Massagué J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
29. Mazières J., Peters S., Lepage B., Cortot A.B., Barlesi F., Beau-Faller M., Besse B., Blons H., Mansuet-Lupo A., Urban T., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J.Clin. Oncol. 2013, 31:1997-2003.
30. Minami Y., Shimamura T., Shah K., LaFramboise T., Glatt K.A., Liniker E., Borgman C.L., Haringsma H.J., Feng W., Weir B.A., et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007, 26:5023-5027.
31. Miyaki M., Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem. Biophys. Res. Commun. 2003, 306:799-804.
32. Mukhopadhyay A., Berrett K.C., Kc U., Clair P.M., Pop S.M., Carr S.R., Witt B.L., Oliver T.G. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014, 8:40-49.
33. Nagashima A., Abe Y., Yamada S., Nakagawa M., Yoshimatsu T. Long-term survival after surgical resection of liver metastasis from lung cancer. Jpn. J. Thorac. Cardiovasc. Surg. 2004, 52:311-313.
34. Nagatake M., Takagi Y., Osada H., Uchida K., Mitsudomi T., Saji S., Shimokata K., Takahashi T., Takahashi T. Somatic invivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 1996, 56:2718-2720.
35. Perl A.K., Wert S.E., Nagy A., Lobe C.G., Whitsett J.A. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl. Acad. Sci. USA 2002, 99:10482-10487.
36. Qin J., Wu S.P., Creighton C.J., Dai F., Xie X., Cheng C.M., Frolov A., Ayala G., Lin X., Feng X.H., et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature 2013, 493:236-240.
37. Sakashita S., Sakashita M., Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. Semin. Oncol. 2014, 41:28-39.
38. Shames D.S., Wistuba I.I. The evolving genomic classification of lung cancer. J.Pathol 2014, 232:121-133.
39. Shi Y., Hata A., Lo R.S., Massagué J., Pavletich N.P. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997, 388:87-93.
40. Shimshek D.R., Kim J., Hübner M.R., Spergel D.J., Buchholz F., Casanova E., Stewart A.F., Seeburg P.H., Sprengel R. Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 2002, 32:19-26.
41. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
42. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
43. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., Stevens C., O'Meara S., Smith R., Parker A., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431:525-526.
44. Su Y.C., Hsu Y.C., Chai C.Y. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J. Med. Sci. 2006, 22:14-19.
45. Sutherland K.D., Berns A. Cell of origin of lung cancer. Mol. Oncol. 2010, 4:397-403.
46. Takeuchi T., Tomida S., Yatabe Y., Kosaka T., Osada H., Yanagisawa K., Mitsudomi T., Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J.Clin. Oncol. 2006, 24:1679-1688.
47. Tascilar M., Skinner H.G., Rosty C., Sohn T., Wilentz R.E., Offerhaus G.J., Adsay V., Abrams R.A., Cameron J.L., Kern S.E., et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2001, 7:4115-4121.
48. Teng Y., Sun A.N., Pan X.C., Yang G., Yang L.L., Wang M.R., Yang X. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. Cancer Res. 2006, 66:6972-6981.
49. Tseng R.C., Chang J.W., Hsien F.J., Chang Y.H., Hsiao C.F., Chen J.T., Chen C.Y., Jou Y.S., Wang Y.C. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int. J. Cancer 2005, 117:241-247.
50. Walker S. Updates in non-small cell lung cancer. Clin. J. Oncol. Nurs. 2008, 12:587-596.
51. Xu C., Fillmore C.M., Koyama S., Wu H., Zhao Y., Chen Z., Herter-Sprie G.S., Akbay E.A., Tchaicha J.H., Altabef A., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25:590-604.
52. Yanagawa N., Leduc C., Kohler D., Saieg M.A., John T., Sykes J., Yoshimoto M., Pintilie M., Squire J., Shepherd F.A., Tsao M.S. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J.Thorac. Oncol. 2012, 7:1513-1521.
53. Yanagi S., Kishimoto H., Kawahara K., Sasaki T., Sasaki M., Nishio M., Yajima N., Hamada K., Horie Y., Kubo H., et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J.Clin. Invest. 2007, 117:2929-2940.
54. Yang X., Li C., Herrera P.L., Deng C.X. Generation of Smad4/Dpc4 conditional knockout mice. Genesis 2002, 32:80-81.
55. Zhang Y.W., Staal B., Su Y., Swiatek P., Zhao P., Cao B., Resau J., Sigler R., Bronson R., Vande Woude G.F. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 2007, 26:269-276.
56. Zhang Y.W., Staal B., Dykema K.J., Furge K.A., Vande Woude G.F. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation. PLoS ONE 2012, 7:e38955.